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Abbreviations 
 
Allo-HS  Human allogenic serum 
ASCs  Adipose derived stromal cells 
AT-MSC Adipose tissue derivedmesenchymal stromal cells 
Auto-HS Human autologous serum 
BM-MSC  Bone marrow derived mesenchymal stromal celles 
BMSCs  Bone marrow derived stromal cells 
CPC Centre de Production Cellulaire 
EMA European Medicines Agency 
EUTCD European Tissue and Cell Directive 
FBS  Fetal bovine serum 
FDA Food and Drug Administration 
GMP Good Manufacturing Practice 
hMSCs  Human mesenchymal stromal cells 
HPL  Human platelet lysate 
ITS  Insulin–Transferrin–sodium Selenite supplement 
PC Platelet concentrates 
PD  Population doubling’s 
PDT  Population doubling time 
SFM  Serum-free media 
tPRP   Thrombin activated Platelet Rich Plasma 
XFM  Xeno-free media 
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Introduction 
Cell culture began in the 19th-century when a physiologist, Sydney Ringer, developed a solution capable 
of maintaining a beating frog heart outside of the body. He was able to maintain the tissue under living 
conditions by submerging in an isotonic salt solution composed of sodium chloride, potassium chloride, 
calcium chloride and sodium bicarbonate. (1)  A buffering system, usually phenol red, was also added to 
the culture media in order to monitor a pH at physiological ranges. In the years 1907 to 1910, specific 
methodology for cell culture was established by Ross Granville Harrison. He was the first to be able to 
observe neural growth. In his experimentation, he placed fragments of embryonic tissues from frog 
medullary cords on cover slips of glass slides and sealed them with clotted lymph. He indeed generated 
the first moist chamber. (2)  Apart from the nutrition, animal cells also need specific culture conditions; 
they are kept in incubators in a controlled humidified gas mixture of 5% CO2 and 95% O2 under a 
physiological temperature of 37° C. The CO2 is essential to maintain the pH of media because without 
CO2 the medium becomes alkaline and compromises cellular survival and proliferation. 
Cell culture techniques made significant advances in the 1940s and 1950s to support research in 
virology. As viruses require the components of infected cells to reproduce themselves, large scale 
manufacturing of viral material in safe conditions necessitates co-culture with animal cells. For instance, 
the vaccine for Polio was produced with the aide of co-cultured fetal cells. Harry Eagle, an American 
pathologist, defined the minimal requirement in 1955 for the Hela cell line (isolated from a human 
uterus Carcinoma at Johns Hopkins Hospital) and mouse fibroblasts, laying down the fundamental 
principles of mammalian culture. Eagle proved that 27 elements were essential for the growth of 
mammalian culture, and his medium Eagle’s minimal essential medium (Eagle’s MEM) contains various 
amino acids, glucose, vitamins, isotonic salt solutions and an whole animal or human serum. (3)  All of 
the elements were defined as the base medium without the serum component. Dulbecco formulated a 
modified version of the Eagle’s MEM, Dulbecco’s MEM (DMEM) around the same time period, with 4 
times more vitamins as reported in Table 1. Historically cell culture has been done with the addition of 
serum to the culture medium to mimic the physiological condition of the body. The source of the serums 
can differ; it can be human serum, horse serum or cattle serum among the most common.  
Serum provides the cells with nutrients, attachment factors, growth factors and hormones, binding and 
transport proteins, spreading factors, fatty acids, lipids and protease-inhibitors. All of these factors are 
essential for proliferation and differentiation of cells in culture systems.  
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Inorganic salts  MEM DMEM 
CaCl2 200 200 
KCl 400 400 
MgSO4 98 97.67 
NaCl 6800 6400 
NaCO3 2200 3700 
NaH2PO4 140 125 
Fe(NO3)3 - 0.1 
L-Amino acids 
  
Arginin 126 84 
Cystine 31 63 
Histidine 42 42 
Isoleucine 52 105 
Leucine 52 105 
Lysine 73 146 
Methionine 15 30 
Phenylalanine 32 66 
Threonine 48 95 
Tryptophan 10 16 
Thyrosine 52 104 
Valine 46 94 
Glutamine - 584 
Glycine - 30 
Serine - 42 
Vitamins   
Cholin 1 4 
Folic Acid 1 4 
Nicotinamide 1 4 
Pantothenic acid 1 4 
Pyridoxal 1 - 
Thiamine 1 4 
Riboflavine 0.1 0.4 
Inositol 2 7.2 
Miscellaneous 
  
D-Glucose 1000 4500 
Phenol red 10 15 
 
Table 1: Composition of Eagle’s MEM and the Dulbecco’s MEM Medium. Adapted from  ref 1 and Yang and Xiong 
culture conditions and types of growth media for mammalian cells, 2012) 
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Fetal Bovine Serum  
Serum is an essential requirement of mammalian cell culture since the beginning of the technique. Until 
now, Bovine serum is the most wildly used in cell culture, including, bovine calf serum, newborn calf 
serum and fetal bovine serum (FBS). Fetal bovine serum provides the highest quality because the fetus is 
not exposed to the outside environment and therefore presents low antibodies and complements. The 
main components of the serum are listed in Table 2. 
  
 
 
Table 2: The main components of serum and their mean concentration. Zhanqiu Yang and Hai-Rong Xiong. Culture 
Conditions and Types of Growth Media for Mammalian Cells. "Biomedical Tissue Culture", book edited by Luca 
Ceccherini-Nelli and Barbara Matteoli, ISBN 978-953-51-0788-0. 
For the clinical application of cell therapies and tissue engineering, reliable and safe cell culture methods 
are needed. Indeed the quality and safety of cell products are dependent on how they were obtained 
and how they are cultured over time.  
An investigation on commercially available FBS has shown that a high degree of serum variability was 
present both within and between suppliers in all major categories investigated (see Figure 3). Therefore, 
caution should be employed in the interpretation of results from experiments using serum supplements 
without specific quantification of possible interfering or modulating factors. (4) 
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Figure 3: Variabiliy between 3 batches of serum (picture from UTR).Fibroblast cells were grown for 2 weeks with the 
same concentration of serum from 3 separate sources to evaluate overall cell growth. Cells were plated in triplicate,  
fixed in alcohol and stained with Giemsa to assess overall growth.  
A recent study using proteomic analyses has shown that the composition of FBS varies over time in  
culture medium. The amount of several extracellular matrix and structural proteins, which are indicators 
of cell growth, decreased. (5)  This vast batch-to-batch variability and the primitive control tools used by 
suppliers (such as testing osmolality, presence of endotoxins, and growth promoters) can be responsible 
for phenotypical differences in the cell culture and make it difficult to compare results from one 
laboratory to another. Secondary treatments of FBS, such as heat inactivation (30 minutes at 56°C with 
mixing to inactivate complement), can also induce metabolic and morphologic changes in cell cultures. 
For example, lymphoblasts show significant differences in their proteome accordingly if they were 
cultured in heat inactivated FBS or not. (6)  FBS is also associated with a risk of transmitting various 
infectious agents, such as prion or virus.  In fact, it has been reported that as much as 20-50% of 
commercial FBS is virus-positive. (7)  Bovine proteins can also be internalized by the cultivated cells or 
can attach to their membrane which may lead to immunological reaction after cell transplantation. 
Specifically, a single injection of 100 million hMSCs grown under standard conditions (20% FCS) can carry  
between 7 to 30 mg of calf serum proteins, and rats who received several doses of HM-MSC showed 
strong immunoreactivity against bovine serum albumin.(8)  Indeed, patients treated with lymphocytes 
cultured in FBS have developed anaphylactic or arthritis-like immune reactions(9); and cardiomyoplasty 
with skeletal myoblasts grown in an FBS enriched medium was shown to cause ventricular arhythmias 
and sudden death in patients. (10)  However, the majority of clinical studies have been accomplished 
with MSCs expanded in media containing FBS, and were performed without the appearance of major 
side effects. Apart from the technical problems mentioned above there is an ethical issue about the 
collection of FBS as it is harvested from bovine fetuses taken from pregnant cows during slaughter. It is 
obtained through a cardiac puncture without any form of anesthesia. Therefore, it could be imagined 
Batch A 
Batch B 
Batch C 
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that fetuses are exposed to suffering during harvesting, so the current practice of fetal blood harvesting 
has been described problematic. (11)  
FBS availability is also limited, as a byproduct of meat processing industry, many factors will impact the 
annual harvest, such as:  
• Weather-induced cattle sell-offs (drought and harsh winters) 
• Cattle retention (ample forage and government intervention in the agriculture market) 
• Dairy cow buy-outs to reduce milk production 
• Increasing milk and meat demand(12) 
 
Two mega corporations control production and distribution of FBS worldwide. Associated with an 
increasing demand it could be imagined that high and volatile prices are expected for the next decade. 
Currently, one liter of clinical-grade Australian/ New Zealand serum costs over 1300 US dollars. (13) 
Regulatory Framework 
All tissues cultured within cell culture systems have to trace all elements that come into contact with the 
tissue from the beginning of harvest.  Therefore, all nutrient media, growth factors and serum have to 
be of high clinical-grade quality if the cells are to be used in therapeutic applications. 
There are different regulations world-wide but many have common ground. 
USA 
In the USA, human cells and tissues and cellular- and tissue-based products fall under the Code for 
Federal regulation 21, part 1270 and 1271. Examples include, but are not limited to, bone, ligament, 
skin, dura mater, heart valve, cornea, hematopoietic stem/progenitor cells derived from peripheral and 
cord blood, manipulated autologous chondrocytes, epithelial cells on a synthetic matrix, and semen or 
other reproductive tissue. Food and Drug Administration (FDA) requires firms to register and list their 
products. It also requires tissue establishments to evaluate donors, through screening and testing, to 
reduce the transmission of infectious diseases through tissue transplantation. Finally, it establishes 
current good tissue practices for cell and tissue-derived products. Development and clinical application 
will undergo specific regulation and is associated with the Center for biological evaluation and research, 
a subdivision of the FDA. 
More information can be found under following this link: 
http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?CFRPart=1271&showF
R=1 
Europe 
The European tissue and cell Directive (EUTCD) is made up of three Directives, the parent Directive 
(2004/23/EC) which provides the framework legislation and two technical directives (2006/17/EC and 
2006/86/EC), which provide the detailed requirements of the EUTCD. The directives set a benchmark for 
required standard when using tissues or cells for human application. This directive sets traceability 
requirements, notification of serious adverse reactions and events and certain technical requirements 
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for the coding, processing, preservation, storage and distribution of human tissues and cells. It applies to 
tissues and cells including haematopoietic peripheral blood, umbilical-cord (blood) and bone-marrow 
stem cells, reproductive cells (eggs, sperm), fetal tissues and cells and adult and embryonic stem cells. 
Blood and blood products are not concerned by this directive. Besides this directives the European 
Union (EU) has set quality standards known as Good Manufacturing Practice (GMP) 2001/83/EC to 
ensure that medicinal products are consistently produced and controlled against the quality standards 
appropriate to their intended use. Also, products made for research purpose are concerned. The 
products are controlled and validated by the European Medicines Agency. Compliance with these 
principles and guidelines is mandatory within the European Economic area. Switzerland as a third 
country (non member of the EU) has requested the EU to assess that its regulatory framework was 
applicable to substances exported and that the respective control and enforcement activities ensure an 
equivalent level of public health protection. This assessment was successfully performed in 2012. 
More information can be found under the following link: 
http://eur-lex.europa.eu/legal-content/EN/TXT/?qid=1404288944041&uri=CELEX:52009DC0708 
Switzerland 
In Switzerland, tissue engineering and cell therapies are regulated within the Transplantation Law, 
together with associated directives. Manufacturing, distributing, marketing of cells therapies and tissue 
engineered products requires an authorization from Swissmedic and compliance to Good Manufacturing 
Practice and good documentation practice. Clinical trials have to be notified to Swissmedic and must be 
carried out in accordance with the guideline for Good Clinical Practices (GCP). Swissmedic must also be 
notified for any problem or accident. (14)  Transplantation of cells and tissue from embryo or fetal origin 
are also submitted to authorization of the federal office for public health. 
More information can be found under the following link:  
https://www.swissmedic.ch/bewilligungen/00155/00242/00243/00245/00246/00249/index.html?lang=
fr 
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Aim of the present study 
Due to the previous exposed points there have been many attempts in replacing FBS with other 
products of different origins over the last years. In the following study we will try to have an overview of 
the existing options provided by the literature for the latest research with a special focus on adult 
human multipotent mesenchymal stem cells (hMSC) and multipotent adipose tissue-derived stem cells 
(ASC). Indeed, most of the research accomplished to date for the replacement of FBS was done on these 
two types of cells. However, many of the results can be extrapolated to other cells types and particularly 
primary cell cultures. 
This work is based on a complete review of scientific articles. Two research engines were used: Pubmed 
and Sciencedirect. The principal key words used were the following «FBS; serum free; mesenchymal 
stem cells (MSC); human platelet lysate (HPL); serum-free chemically defined media”. The obtained list 
has then been completed with a manual research of supplementary references, focused on English 
articles dating within the last 10 years. The bibliography of retained articles was then further examined 
in order to extend the research. The free online media database was also consulted, permitting to see 
how commercial products were classified and the amount of information given by the Manufacturer. 
Explanations about the incoming challenges in tissue regeneration are also given for an immersion in the 
field and focus on the future to increase security for the patient. 
An illustration of the adaptation procedure will be exposed at the end of this study. The Regenerative 
Therapy Unit of the CHUV is evaluating some of the different solutions to replace FBS in tissue 
engineered skin substitutes for severe burns, with both keratinocytes and fibroblast skin cells. We will 
show a first experimental part with the testing of 2 different lots of FBS for cell culture. Then, we will 
expose different results concerning the testing of PRP and human platelet lysate as potential 
replacement of FBS and finally we will report the evaluation of commercially available serum free 
mediums.  
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Serum Substitute Possibilities 
In the last decade, because of the ever increasing potential of problems caused by FBS in cell culture and 
in the aim to apply new cGMP legislation there has been a steady interest of FBS ersatzes. 
Unfortunately, new alternative culture media often does not use a standardized terminology. Not 
knowing what the products contain, or what is exactly meant under which abbreviation can lead to 
confusion. It also appears that media manufacturers promote ambiguous and attractive terminologies in 
order to attract more customers, thus maintaining the actual current confusion. 17  Therefore, a brief 
summary of standardized classification is summarized in order to have a clear overview of existing 
products, the following classification is the one used by Kinzebach and Bieback. (expansion 15) 
Serum-free media 
Undefined culture media that is not supplemented with serum but may contain proteins fractions (eg. 
animal tissue or plants extracts) such as bovine/porcine pituitary extract, chicken embryo extracts etc. 
(15)  Non-protein constituents may also originate from animal sources and the elimination of animal-
derived protein elements is not enough to guaranty a xeno-free media. (16)  For the reasons mentioned, 
the risk of transmitting xenogenic proteins and pathogens by serum-free media remains unchanged 
compared with FBS supplemented culture media. 
Xenogenic-free media 
Also called humanized culture medium. So far human plasma, serum, cord blood serum and platelet 
derivatives have been tested to replace FBS.  Also, xenogenic-free media are undefined. 
Animal-derived component free 
Media containing no components of animal origin, they are not necessarily chemically defined (such as if 
they contain bacterial or yeast hydrolysates or plant extracts). 
Chemically defined media 
Do not contain proteins; hydrolysates or any other components of unknown composition. Hormones or 
growth factors added can be of either animal or plant origin or recombinant products. A chemically 
defined media using recombinant products represents the ultimate aims in cell culture, as all the 
components are well defined and characterized. This allows full standardization with the highest 
possible safety grade. 
In order develop a serum-free medium for mammalian cell culture J. van der Valk et al. (2010) proposed 
a pyramidal approach with an incrementing specificity of media composition (Figure 4). He 
recommended to start a new formulation with 50:50 (v/v) mixture of DMEM (Dulbecco’s Modified 
Eagle’s Medium) and Ham’s nutrient mixture F-12 plus an ITS supplement (insulin, transferring and 
  
selenium). Coating of the culture vessel with extracellular matrix components, 
fibronectin, would also be possible
Addition of specific hormones and growth factors, depending on the cell type sometimes could be 
added to the media and is often required. 
conditions required a gradual lowering i
capable to grow in serum-free media the author recommend
and functioning during the adaptation process
Indeed “different isolation methods and culture conditions may lead to multiple MSC populations with 
slightly different biological and functional characteristics. Differences in culture medium or supplements, 
plating density, level of confluency at cell detachme
expression of surface makers or differentiation capacity
Figure 4: Pyramidal approach to build a serum
Optimization of chemically defined cell culture media 
vitro methods. 
 
 in order to furnish ample cell attachment fa
Therefore, adaptation of cells lines to the new culture 
n serum concentration. To detect unwanted selection of cells 
ed close monitoring 
 (Table 3). (17)  
nt may influence their proliferative capacity, 
.” (18) 
 
-free medium. Inspired from van der Valk
– Replacing fetal bovine serum in mammalian in 
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Medium Constituent Animal source Non-animal substitute 
Insulin K Bovine/porcine pancreas Bovine or human recombinant 
Transferrin K 
Bovine, porcine or human plasma 
fraction 
Inorganic iron carriers/chelates 
Serum protein fractions K F 
(e.g., albumin, fetuin, lipoproteins) 
Bovine or other animal serum 
Lipid delivery alternatives 
 
Plant-derived hydrolysates 
Protein hydrolysates Lactalbumin, peptones, casein Plant-derived hydrolysates 
Lipids/sterols Ovine/human cholesterol 
Plant-derived sterols 
 
Synthetic and plant-derived fatty 
acids 
Growth and attachment factors K Murine/bovine organ digests 
Recombinant factors 
 
Collagen precursors 
Amino acids (e.g., tyrosine, Human hair; Avian feathers; Bovine Recombinant, synthetic or 
Coating agent Animal source Non-animal substitute 
cyst(e)ine, hydroxyproline) 
collagen; Bovine/porcine bone 
gelatin 
plant-derived amino acids 
Reactives Animal source Non-animal substitute 
Surfactants (e.g., Tween 80) Bovine tallow Plant-derived polysorbate 
Dissociating enzymes (e.g., trypsin)  
K F 
Porcine pancreas Plant-derived enzymes 
 
Microbial enzymes   
K stands for used in Keratinocyte culture. 
F stands for used in Fibroblast culture.  
 
Table 3. Common cell culture media constituents and reagents derived from animal sources(16) 
 
To ensure a total xeno-free culture, not only FBS but all the above mentioned media constituents need 
to be replaced by plant derived, recombinant or synthetic products. FBS products are by far not the only 
components that need to be replaced. 
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Human Blood Derivatives 
All the humanized culture media which use blood derived products are submitted to the same national 
legislation as normal blood donation. As a consequence, safe use in clinical applications depends 
strongly under which conditions blood products are locally obtained. In Switzerland, three essential 
principles are applied in order to guaranty safety of blood products. 
1) Selection of donors, according to the World Health Organization (WHO) donation has to be done on a 
volunteer basis, without reward or payment. Selection of donors is done via a questionnaire before 
every blood donation. The questionnaire has been elaborated with the aim of detecting high risk 
situations or behavior which could lead to a temporary or definitive exclusion from blood transfusion 
programs.  
2) Laboratory testing of blood products. All blood products are routinely tested for the following 
pathogens after donation:  AC anti-HIV1, AC anti-HIV2, AC anti-HCV, AgHBS, AC anti Treponema 
Pallidum. 
3) Pathogen inactivation. Currently more than 25 blood transmissible pathogens exist and for the 
majority of them no detection methods exist. It can also occur that pathogen charge is too low to be 
detectable by conventional testing, such as in the first phase of an infection. This is why pathogen 
inactivation procedures make sense, allowing the inactivation of the broad spectra of potential unknown 
pathogens, whether they are fungal, bacteria, virus or parasites. Pathogen inactivation works in the 
following manner; first an intercalating agent is added to the blood product to link to the RNA or DNA of 
the pathogens. Further light activation of the intercalating agent provokes a block in transcription or a 
nucleic acid desaturation and these steps lead to final pathogen inactivation. (19)  
The current method used at our hospital to block the reproduction of pathogens is the Intercept Blood 
System (Cerus Corporation, Concord CA, USA). This technique implies a photochemical component: 
Psoralen amotosalen and long range UVA irradiation. The amotosalen is added to the blood donation, 
then it binds DNA and RNA before being activated with pure UVA light (figure 5). Covalent bonds 
between pyrimidic base residues block further transcriptions of any pathogen.  
 
 
 
 
Figure 5: Intercept mode of action. 
http://www.interceptbloodsystem.com/product-
overview/amotosalen-mechanism-of-action 
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The Intercept Blood System has been proven efficient in reducing the risk of transfusion transmitted 
disease and preventing the occurrence of Graft versus Host Disease (GvHD). Specific studies of platelet 
function also have shown that pathogen inactivation did not hinder the haemostatic capacities of 
treated platelets. The documented reduction of infection risk through this efficient method allowed the 
CHUV to expand the shelf-life of platelet concentrates from five to seven days. (20)  
  
 
 
 
 
 
 
 
 
 
 
Figure 6: Blood components after whole  Figure 7: Blood components after clotting 
blood donation and centrifugation with  of a whole blood donation.  
addition of an anticoagulant.  
 
Human Platelet Lysate (HPL) and Platelet Rich Plasma (PRP) 
Platelets are small circulating enucleated particles, essential for blood coagulation, wound healing and 
tissue repair. They are released in the blood stream through the apoptosis of progenitor cells called 
megakaryocytes, they circulate for 7-10 days before being replaced.  
“Platelets play a critical role in normal hemostasis by forming the hemostatic plug that initially seals 
vascular defects, and by providing a surface that recruits and concentrate activated coagulation factors.” 
(21) After a vascular injury, platelets are activated through the contact with ECM constituents and 
undergo the following stages:  1) Platelets adhesion to ECM via von Willebrand factor; 2) Secretion via 
degranulation; 3) Platelet aggregation.  
The platelet granules contain a cocktail of various substances such as fibrinogen, fibronectin, 
coagulations factors, platelet-derived growth factor (PDGF), TGF-β, ionized calcium, histamine, serotonin 
and epinephrine. (21)  PDGF stimulates proliferation and chemotaxis of neutrophiles, macrophages, 
smooth muscle cells and fibroblasts to the wound site. (22)  Due to the high content in platelets, and 
thus in growths factors, PRP is believed to have a therapeutic effect on wound healing. A systematic 
review about the efficiency and safety of autologous PRP in several clinical areas such as oral and 
maxillofacial applications, chronic skin ulcer, and wound healing after surgery concluded that tissue 
regeneration was significantly improved in chronic periodontitis and chronic skin ulcer. (23)  Platelet 
Plasma  
(55% of total blood) 
Buffy Coat 
Leukocytes and platelets 
(<1% of total blood) 
Erythrocytes 
(45% of total blood) 
Serum 
Clotted blood 
(Platelets, erythrocytes, 
coagulation factors, ect.) 
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derived products are a suitable alternative for FBS.  Indeed, many attempts in replacing FBS by platelet 
derived products in MSC cell culture were shown to be successful.  
Human platelet lysate (HPL) 
Human platelet lysate (HPL) can be obtained from sources such as single donor apheresis platelet 
concentrate or from whole blood donations using buffy coat-derived platelet concentrates.  
Alternatively, it can also be from plasma reduced concentrates with platelet additive or human albumin. 
(15)  “When HPL is used for the expansion of cell therapeutics the donors have to fulfill the respective 
national regulation for blood donation.” (24) 
As there is not any established production method of HPL, each laboratory develops their own 
processing and end-product. This can possibly lead to differences in the proprieties of the HPL obtained 
and make it difficult in comparing outcomes. Therefore, we will attach a summary of production 
possibilities associated to the clinical result outcomes. Protocols for HPL production from buffy coats 
and apheresis derivate platelet concentrates are accomplished through freeze thaw cycle or chemical 
lysis which causes disruption of platelet membranes and release of growth factors. In a second step, 
centrifugation and filtering is needed to remove the platelet particles and membrane antigens; which 
bear the threat of alloimmunization against platelet antigens in vivo. (24)  Indeed, various immune-
mediated platelet disorders have been described such as thrombocytopenia, pos-transfusion purpura 
and platelet transfusion refractoriness.  
A study comparing pooled whole blood derived PC to apheresis PC could not highlight any notable 
differences in the cytokine content or stimulation of MSC proliferation. The optimal HPL concentration 
for cell growth was determined to be approximately 10%. This study also showed the major synergic 
role played by PDGF, TGF-B1 and bFGF in MSC proliferation.  If all factors were inhibited together, the 
HPL stimulating effect decreased by 75%. However, combination of recombinant PDGF, TGF-B1 and 
bFGF could enhance cell proliferation alone. Another interesting factor is that PC could be conserved up 
to 18 months without significant degradation or changes. (25) 
Expired blood bank platelet concentrate can also be used in HPL production with the same efficiency as 
HPL from fresh platelet concentrates and thus without competing with the needs of patients for platelet 
transfusions. In fact, differentiation potential, cell surface antigen and immunomodulatory functions of 
BM-MSC remained unchanged in fresh and expired HPL supplemented cultures. (26)  Moreover, the 
average generation time between population doubling was shorter in cultured cells and hence an 
increased proliferation potential of HPL when compared to FBS. Nevertheless, some differences could 
be detected. Osteogenic marker gene RUNX-2 expression was higher and cells showed morphological 
changes with more spindle shaped, elongated cell structure and showed denser cell-bodies. Also, the 
growth pattern of cells was modified to a mesh-like pattern with circular areas of no cell growth. (26)  
Another study was done investigating BM-MSC culture. The cumulative number of cells until senescence 
was much higher in HPL containing media, but there was a decrease in adipogenic differentiation. 
Immunosuppressive activity was retained and microarray data confirmed the observation of rapid 
growth. Optimal number of thrombocytes needed for HPL- preparation was estimated at 1.5 x 109 /mL 
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with a proportion of 5% in cell culture but granular deposits in culture made the microscopic 
observation difficult. Pooling of PRP and titration of platelet concentration was shown to be a good way 
to normalize the amounts of growth factors and cytokines delivered by the end product. (27) 
Schallmoser et al. produced 3 to 3.5L of pooled PRP from at least 50 donors, with a platelet 
concentration of 0.95x109 +/- 0.15x109 per mL. After, further manipulations were needed to obtain HPL, 
and BM-MSCs were then cultivated in an α-MEM media supplemented with 10% HPL and heparin. The 
proliferation rate of HPL-BM-MSCs was delayed until the sixth day, and further enhancement of 
proliferation resulted in a higher BM-MSC harvest. Morphological differences such as smaller more 
elongated cells could be noted, but these differences were not transposed into relevant 
immunophenotypical changes. Osteogenic and adipogenic differentiation potential remained 
unchanged. Tumorigenicity was tested by long term expansion, without the appearance of immortal 
cells. Also, subcutaneous injection of BM-MSCs in athymic nude mice with final animal dissection after a 
90 days observation period was unable to find any tumor. (28)  Further investigation of long term BM- 
and UCB-MSCs cultivation showed that phenotypical and functional characteristics of cells remained 
stable with HPL. Genetic studies were not able to find any chromosomal abnormalities, and telomere 
length decreased among the different passages with an absence of telomerase activity. (18) 
When preparing HPL, pooling of PRP is recommended in order to diminish inter-individual differences in 
the amount of growth factors and cytokines delivered by each product lot. Cryopreservation of HPL also 
allows to re-test donors 3 month after blood donation for infectious markers. (29)  Donor age can also 
have an impact on HPL quality. Indeed, umbilical cord PRP has been shown to have a higher 
concentration of mitogenic factors than adult PRP. Thrombocyte concentration will also be a 
determining factor in the amount of growth factors delivered by HPL. Comparison of different 
thrombocytes concentrations pointed out that a platelet concentration below 1,5 x 109 /mL reduced the 
pro-proliferative effect. Various pathogen reduction protocols have been established using 
photochemical treatment, without any difference in MSCs quality. (30) 
Platelet Rich Plasma (PRP) 
A recent study has concluded that thombine activated PRP was a suitable alternative to FBS in AT-MSC 
cell culture. Pooled buffy-coat platelet concentrates were activated alternatively through human 
thrombin, ADP/ epinephrine or TRAP-6 before being centrifuged and filtered. Out of these three 
products, thrombin activated PRP (tPRP) was determined as being the most efficient inducing agent with 
an expansion of 2.8 times higher than that of FBS. The authors point out that thrombin activation 
proceeded similar to physiological activation of platelets and thereby ensures the bioactivity of secreted 
growth factors. In addition, this method avoids the formation of platelet membrane aggregates, and the 
transfer of platelet membrane antigens. (31)  ASCs maintained their tri-lineage differentiation capacity 
and immunophenotype. Colony forming units were similar to FBS, however with distinct cell densities 
and size. Nevertheless, results obtained with BM-MSC were more ambiguous, with a documented 
decrease in osteogenic differentiation. (30) 
Comparison of platelet rich plasma concentration levels needed for ASCs and human dermal fibroblasts 
growth showed an optimal cell proliferation at 5% tPRP. Proliferation declined in a dose-dependent 
  
manner in the presence of 10% or 20% tPRP. The level of PDGF
times higher than those before platelet
(tPPP) was also capable of supporting an enhanced cell proliferation co
Figure 6: production of PRP in our laboratory based on the Standard Operating Procedure.
Human plasma 
There are only few articles using plasma in MSC culture. 
been shown to be more effective than plasma in stimulating cell proliferation. 
many factors promoting cell proliferation are released 
processes. (33) 
A study using 10% autologous plasma was able to expand BM
differentiation capacity (adipogeni
Human serum 
Human allogenic serum 
Two studies using commercial allogenic serum as a culture supplement have shown 
attached but were not able to 
divisions. Unfortunately, neither of 
and tests performed(8,35)and further interpretation of these results 
On the other hand, a well documented study 
typed donors, screened for the absence of HLA allo
FBS. AT-MSC cultured with AB-HS showed different morphology and growth pattern
smaller and spindle-shaped with fewer cytoplasmic processes than cell
-AB and TGF-β1 were 187 times and 81 
-rich plasma activation. (32)  Activated platelet poor plasma 
mpared with inactivated PRP.
As a matter of fact, natural clotted serum 
through platelet activation and clotting 
-MSC with a maintained tri 
c, chondrogenic, osteogenic). (34) 
form colonies. They were unable to expand and died after few cell 
the studies provided more information about the serum preparation 
is therefore 
compared pooled HS (from at least five AB
-antibodies and full fitting blood donor regulation) to 
s cultured with FBS, had a distinct 
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This is likely because 
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that fewer cells 
difficult.  
-blood-group 
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mesh-like growth pattern and a decreased adhesion potential, and they detached more rapidly from 
plastic after trypsination . The cumulative expansion rates were higher with AB-ALHS than with FBS. The 
differentiation capacity of AT-MSC was preserved and there was not any significant difference in surface 
markers expressed throughout long-term culture. “Therefore AB-HS could be a widely available ersatz 
for FBS in AT-MSC cell culture, with only a few processing steps necessary. In addition, it shows the 
highest proliferative effect compared to FBS.” (31) 
Another study using ASC needed a 15% AL-HS concentration in order to reach the same proliferation 
rate than with 10% FBS. Statistical analysis of expressed surface markers showed no significant 
differences between both medium. However, oesteogenic differentiation capacity was decreased with 
AL-HS, chondrogenic differentiation remained unchanged and adipogenic differentiation was enhanced. 
Indeed, more oil droplets (lipid deposits) could be seen under light microscope and adipogenic markers 
were upregulated. Microarray gene expression analysis of 20,100 genes identified 1281 genes (6.4%) 
which where differently expressed. Significant changes were involved in cell cycle changes and the TGF-
β signaling pathway (genes in this pathway control biological processes such as embryogenesis, 
morphogenesis of tissues like bone and cartilage, and angiogenesis). 27  
Human autologous serum 
The limited availability of autologous blood in weakened patients is the principal obstacle to a 
generalization of human autologous serum in cell culture. “Only 200mL of serum can be gained from a 
500mL blood donation. i.e supplementing medium with 10% AS yields 2L expansion medium. what’s 
enough for a maximal 2-3 weeks expansion period, harvesting sufficient MSC for one to two clinical 
applications.” (27)  
A study analyzing characteristics of BM-HMC cultured in autologous serum pointed out that BM-HMC 
are morphologically and phenotypically equal to those cultured in FBS. On the other hand, proliferation 
rate was increased with a lowered differentiation rate, suggesting that FBS had induced cell lines further 
in the differentiation pathway and the changes in gene expression reflected this difference. Human 
autologous serum also tended to generate a more stable genomic background, with a delayed 
senescence process. 
19, 20
 
W. IM et al. compared the growth of ASCs in auto-HS to FBS and showed that ASCs had a greater 
expansion rate in auto-HS than FBS and that they expressed similar markers and conserved adipogenic 
differentiation capacity. However, chondrogenic and osteogenic differentiation capacities were not 
problematic. (36) 
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Chemically defined mediums 
The serum-free media interactive online database 
De Brunner et al. developed the serum-free media interactive online database 
(http://goodcellculture.com/). The database was an attempt to regroup all the commercially available 
serum-free media and medium supplements, divided in three categories: serum-free media, chemically- 
defined media and animal-derived component free media. The serum-free media were associated with 
different kind of cells through defined attributes such permitting a clear overview of existing products. 
Unfortunately the online database was closed in 2014. 
Several issues have been mentioned about the use of commercial media. Their exact formulation is 
generally not furnished by the supplier and the products can be modified without informing the 
customers. Furthermore, supplements with the same name may differ in composition from one supplier 
to another. (17)  
StemPro® MSC SFM XenoFree, StemPro® LipoMAXTM, Invitrogen 
Two serum-, xeno-free commercial products for the culture of AT-MSC were tested in the reported 
study. After a necessary pre-coating step of culture vessels with CELLstart (Invitrogen®), StemPro® MSC 
SFM XenoFree (SP XF) alone and the lipid-based enriched version: StemPro® LipoMAXTM (XF LM) were 
compared with 10% HS and 10% FBS supplemented culture. The results showed that xeno-free medium 
culture exhibited higher and prolonged proliferation rates while maintaining surface marker expression 
profiles and multipotentiality compared with FBS and HS cultures. Nonetheless, osteogenic 
differentiation capacity of XF LM AT-MSC was decreased, with spontaneous adipogenic differentiation 
occurring. Indeed, the AT-MSC where positive for Oil Red O staining and showed reduced ALP activity. 
According to the authors of the study, more rapid confluence rates may have caused spontaneous 
transdifferentiation. Also chondrogenic differentiation was distinctly established as the condensing 
pellets formed more rapidly than controls. SP XF cells were more homogenous and less scattered and 
had a larger proportion of cells dividing than HS and FBS treated samples. (37) 
Serum replacement 1 and 2, Sigma-Aldricht 
A study comparing 2 potential ersatzes for FBS developed by sigma Aldricht for ASCs culture medium 
showed drastic diminution of proliferation rates with severe alterations in differentiation capacities of 
ASCs. (38) 
GlutaMAXTM, Invitrogen 
Experimentation substituting FBS in ASCs culture with GlutaMAX 1% demonstrated initially a decrease in 
cell growth compared with 10% allogenic human serum substituted cultures. Furthermore cells ceased 
to divide after 4 days and detached themselves from the cell culture flasks.  
  
Experimental section 
The Regenerative Therapy Unit laboratory is currently establishing new techniques for the treatm
burns victims, in particular they develop new products and test FBS substitutes in order to re
Swissmedic standards and increase safety of final
FBS serum testing for primary cell culture
The Regenerative Therapy Unit has to 
used in research and clinical purposes
One FBS serum (Gibco_41F4344K)
different cells lines:  skin progenitor cells (FE002
4.1, adult fibroblasts (NP/JATH-F p4). The growth capability was compared 
(Sigma_011M3396). The culture medium wa
glutamine) and 10% of FBS. Each experiment was done in triplicate.
Cells were seeded at 3 different densities (
dishes. Medium was changed 2 times during the week. 
stained with Giemsa to evaluate cellular confluence. Finally 
(Figure 8). 
Figure 8: Comparison of new FBS lot to control after 
 
 products. 
 
regularly test new batches of fetal bovine serum for cell culture
.  
 was tested for the capability to promote primary cell growth of
-sk2.R, p5.1), Tenocyte progenitor cells (FE002
to the cur
s prepared as follows: DMEM (Gi
 
1,000; 10,000 and 50,000 cells) into 10cm
After 2 weeks of cultivation cells are
cell culture dishes were photographed 
two weeks cultivation.  
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Cell culture images prove that this serum gives the closest result to control serum in this three cell lines. 
Therefore, it can now be used for research purposes on severely burned patients. 
Human blood derived product production and testing 
PRP and HPL 
In this set of experiments, we aimed to evaluate the ability of PRP (platelet rich plasma) and HPL to 
promote cell migration by a scratch test assay. This assay is to represent a “wound model” in vitro. 
250uL of PRP was obtained from the CPC (Centre de Production Cellulaire). 
For the scratch assay, skin progenitor cells (FE002-sk2.R, p3) were seeded on 6 well plates at a density of  
2x105 cells per well in normal growth medium and cultured until they reached 90% confluence. Then, 
the medium was removed and cells were washed 1x with PBS. Once the PBS removed, marks were made 
on the bottom of the well with a marker (Figure 9), to help to find the location of the scratch for the 
photographic follow-up. Wells were washed again with 1x PBS to eliminate the residual scraped cells 
before adding 1mL of medium. Media were prepared as follows: Normal growth medium was composed 
of DMEM, 1% Glutamine and 10% FBS; PRP growth medium was made with DMEM, 5% PRP or 5% HPL 
and 1% Glutamine. The plates were then incubated at 37°C in 5% CO2. Pictures were taken at 0, 24 and 
48 hours after “wounding” with an Olympus X81. The most representative pictures are shown in Figures 
10 and  11. 
 
Figure 9: Schematic of the preparation of the cells for a scratch test assay. 
  
Figure 10: After 24 hrs post-wounding
10% control medium condition. After 48 hours, the scratch zone was completely filled
PRP concentration, organized cell growth was rapid with non
Figure 11: After 24 hrs of wounding a large amount of cells had already migrated into the 
hPL. After 48 hours, the scratch zone was completely filled
growth was more rapid than in the control 10% FBS medium
 
, a large amount of cells had already migrated into the 
 in both conditions.
-altered cell morphology.  
 in both conditions. At the 5% 
.  
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scratch space in the 
 At the 5% 
 
scratch space in the 5% 
hPL concentration, Cell 
  
Example of commercial mediums
In this study, the UTR laboratory technician
seeded 1,500 fibroblasts per well in a 96 well culture dish. The wells were filled with 100 uL of the 
different mediums. 
Cell activity was measured after 
Solution Cell Proliferation Assay 
contains a tetrazolium compound, MTS whi
dye is optimally measurable at an absorbance wavelength of 490 nm.
old media was replaced with fresh media and MTS reagent. Samples were then incubated for 
minutes at 37°C and the absorbance measured at 49
(Tecan) (Figure 12). 
 
Figure 12: One of the US serum
proliferation is notably reduced compare
 
 
 
 
 
 
 evaluated two serum-free media from a US c
0, 4, 7, 14, 18 and 21 days in culture using a Cell Titer 96® AQueous One 
(Promega Corporation, Madison, WI, USA). The reagent of this assay 
ch is reduced by metabolically active cells into a formazan 
 At each measuring time
2 nm using an Absorbance Microplate Reader 
-free medias can be considered for cell culture, even if the cellular 
d to the control medium (DMEM, 10% FBS, 1%
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Discussion 
Obviously, FBS will be replaced by one or more products in the next decade. The optimal product should 
not contain any animal or human components, i.e. be completely defined, show at least similar 
proliferation rates to FBS, not alter the cell function and differentiation capacities and in addition be 
available at a competitive price. From where the leading successor will come is still unknown but it will 
probably be produced by some biotechnological enterprise. Indeed, the current legislation pushes the 
laboratories to promote industrial products to replace homemade preparations to be compliant with 
GMP manufacturing. As all the production steps of a clinical compatible cell therapy have to be validated 
by national control organs and proven GMP compatible, it is much easier to buy a industrial product that 
has already been granted serum-free and GMP compatible than to go through all the validation 
processes with a homemade preparation.  
However, we will expose the following advantages and disadvantages of currently existing ersatzes  
Industrial ersatzes 
Due to the complexity of FBS, the current substitutes developed by industry are rather destined to 
specific cells types than universally adaptable. Therefore, only the most used cell types will have their 
serum-free media while neglecting the exceptions. Furthermore, FBS substitutes are not sold anymore 
as separate components but are rather part of so called “all-in-one” media. On one hand, it can bring 
cell culture to a higher level of standardization, but this can drastically dismiss the possibility of making 
personalized mixing.  
 
Another issue with manufactured products is that their formulation can be modified at any time and 
without necessarily informing their customers. The lack of a standardized nomenclature used by all 
manufactures also makes it difficult to know what the products really contain. The used terms are often 
vague and unclear (for instance serum-free). Most products that are certified as serum-free products 
still contain animal- or human-derived products, therefore it should be carefully checked if the product 
composition is associated with any advantages in terms of biological safety compared to the actual 
medium used. Importantly, it is necessary to test the composition and watch for morphological and 
functional differences in specific cultivated cells.  
It is also hard to know which media are currently on the market and eligible for your cell culture. The 
serum-free media online data base was a good attempt of centralizing all the existing serum-free 
commercial media; however it did not permit to have an overview of the efficiency of registered media 
and has been recently closed. The closure of the database contributes to favor the visibility of major 
players at the detriment of less known brands. A new website working on a cooperative basis would 
improve the information sharing. For instance, by allowing the different research laboratories to 
comment and rank the medium used and also to add links to published research done with cells 
cultured with a specific media. At the moment, no database registering serum-free culture media exists.  
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Lately, some interesting substitutes for ASC culture have appeared. Two commercial media have shown 
already comparable or enhanced proliferation rates than with FBS which was associated without 
significant alteration of cells characteristics: StemPro® MSC SFM Xeno Free and Knockout™ SR.  
Knockout™ SR is guaranteed serum-free. StemPro® MSC SFM Xeno Free is guaranteed xeno-free, 
without further information about their content and what the company understands under the xeno-
free term. Due to their probable content of human derived components, the safety level of those 
products is not necessarily higher than a homemade xeno-free media supplemented with human blood 
derived products. However, it seems an important milestone on the way to animal free and chemically 
defined media. 
Human substitutes 
Many problems have been pointed out resulting from the usage of FBS in cell culture also apply for 
Blood derived products. Indeed, allogenic proteins can also be internalized in cultivated cells and 
possibly lead to immunological reaction after transplantation. Furthermore, the Infection risk also 
remains; indeed human derivate products can also bare infection risk. However, intervention such as 
donor selections and pathogen inactivation permits to diminish to acceptable levels and cGMP 
compatible production. Currently in Switzerland, blood products are routinely tested for AC anti-HIV1, 
AC anti-HIV2, AC anti-HCV, AgHBS, AC anti Treponema Pallidum followed with pathogens inactivation 
with the Intercept Blood System. Further testing might enhance the security of blood products, however 
at higher costs. Similar to FBS, blood derived products also present a high batch-to-batch variability, 
which can be reduced by pooling and titrating of different lots.  
 
There is also an ethical issue about the use blood-derivate products in cell therapy. In most countries 
blood derived products are often a limited resource, used in clinical therapies of many other diseases: 
such as acute blood losses, coagulation troubles, etc. Due to population aging and an increasing demand 
for blood donations, the availability of blood-derived products for research purposes will furthermore 
diminish. In Switzerland, an annual increase of around 10% in the amount of platelets used has been 
reported on average since 2000. (20)  Therefore, it seems improbable that enough blood-derived 
products will once be available for cell culture at an industrial scale, without a drastic increase of blood 
donations.  
 
Using expired platelet concentrates can be a way to avoid direct competition for blood-derived 
products. Actually, validity for HPL issued from expired platelet concentrates has been assessed up to 
seven days. (26)  However, hospitals also tend to expand the validity period of Platelet concentrates for 
transfusion, diminishing the pool of available platelets for research. Platelet derivatives seem to be 
suitable alternatives to FBS. Indeed cells cultivated in HPL and thrombin activated PRP substituted 
culture medium, showed higher expansion rates without significant modification of cell functions and 
characteristics compares to cells grown FBS substituted cell cultures.  
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It seems likely that blood-derived products will be an essential asset in the bridging from animal-derived 
products to full xeno- and human-free products. How long the transition will take to have a fully xeno- 
and human-free product is still unknown.  
The empire strikes back  
Aware of the threat to their business caused by biosafety and ethical issues, 15 FBS producers  created a 
lobbying structure defending their interest; the International Serum Industry Association (ISIA). The aim 
of this association is to standardize serum quality and integrity assessment tests and simplify their 
documentation to establish an appropriate Certificate of Analysis. At the moment, minimum testing 
standards already exist, however ranges of acceptance of the results are broad wich can differ from 
producer to producer. (39) 
Furthermore, the ISIA also propose specific definitions for the origin of slaughterhouse-derived materials 
and donor origin materials. Unfortunately, the ethical issue about possible suffering of fetal bovine 
during harvesting seems to not be a priority. Indeed, no document delivered by the ISIA deals with the 
subject.  
Conclusion  
Ultimately, a chemically-defined media, produced on a large scale in well protocoled and standardized 
steps seems the more appropriate than FBS ersatz. The standardization process would virtually 
eliminate the batch-to-batch variation in the growth factor content. Infection risk would be reduced on 
the bacterial contamination of bioreactors needed in the production of the various components. Cell 
culture would not use any animal or human derived components anymore. In the meantime, use of 
blood-derived products seems a sustainable alternative. To avoid competition with use in routine 
hospital practice, the use of expired platelets in order to produce GMPc compatible HPL and thrombin 
activated PRP, would be recommended. Expired platelets also present the lowest possible cost, taking 
into the fact that they are thrown away if not used. For ASCs StemPro® MSC SFM Xeno Free 
Supplement, StemPro® with LipoMAXtm Defined Xenofree Lipid Supplement can already be used as an 
alternative to FBS, with a clear improvement of certain cell type proliferation. 
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